Informations générales (source: ClinicalTrials.gov)
Measure of Intracranial Pressure Variations During Migraine Attacks (MigICP)
Observational
University Hospital, Clermont-Ferrand (Voir sur ClinicalTrials)
juillet 2014
juillet 2018
29 juin 2024
An increase in intracranial pressure (ICP) during migraine attacks is possible and could
contribute to pain initiation and maintenance. From now on, it was not possible to
measure ICP in a non-invasive way. The development of a new tool allows non-invasive
self-measures of ICP variations. Thus, it is possible for the first time to look for such
ICP variations during migraine attacks and to conclude if this mechanism is implied in
the pathophysiology of migraine.
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CHU Clermont-Ferrand - 63003 - Clermont-Ferrand - Auvergne - France | Patrick LACARIN | Contact (sur clinicalTrials) | |||
Critères
Femme
Inclusion Criteria:
- 18 to 50 non menopausal women
- Menstrual migraine
- Using a triptan as usual treatment to relieve attacks
- Usual triptan efficacy although recurrence is possible
- 18 to 50 non menopausal women
- Menstrual migraine
- Using a triptan as usual treatment to relieve attacks
- Usual triptan efficacy although recurrence is possible
- Disease of the ear
- Intracranial hypertension
- Chronic daily headache
- Use of topiramate or acetazolamide
- Triptans used more than 10 days/month
- Analgesic drug used more than 15 days/month
- Uncontrolled high blood pressure
- BMI >30
- Ongoing allergic rhinitis or flu